News

Gleason serves as Financial Advisor in Chapter 11 Bankruptcy of Geo. V. Hamilton, Inc.

May 31, 2018

On March 30, 2018, McKees Rocks-based Geo. V. Hamilton, Inc., a commercial and industrial insulation and distribution contractor, announced that it had exited Chapter 11 bankruptcy under a confirmed plan of reorganization.  Gleason Experts acted as a financial consultant to the Future Claimants’ Representative and the Official Committee of Asbestos Personal Injury Claimants.  As part...   Read More

Tags:  Featured , Gleason Experts

Mid-Year Market Update: July 2018

July 18, 2018

Market Review and Outlook The M&A market had a huge first half of 2018, with total announced deal value reaching a record of $2.5 trillion - a 61% increase over the first half of 2017.  While overall value is up this year, deal volume slowed by nearly 4% from the same period in 2017.  This drop continues...   Read More

Tags:  Featured , Gleason Advisors , Uncategorized

2017 Year-End Financial Market Review

January 8, 2018

Optimistic Investors Cheered 2017 Across the Globe, Tax Reform Sets the Stage for Strong Economic Growth in 2018  [SEE FULL REPORT...] While it seems like a lot happened in 2017, in retrospect we struggled to find any one event that defined the year... that is until Tax Reform passed.  The Trump Presidency had its inaugural...   Read More

Tags:  Gleason Advisors

M&A Market Update

June 20, 2017

The Middle Market Environment: Mergers & Acquisition activity in the middle market has remained incredibly high relative to historical levels.  However, the market has retracted from peak levels over the last two years, with the total number of transactions decreasing 3.1% and 12.8% in ’15 & ’16, respectively.  The 1st quarter 2017 was down 8.2%...   Read More

Tags:  Gleason Advisors

Trends in ADR and the Role of Financial Experts

January 1, 2017

The U.S. District Court for the Western District of Pennsylvania implemented Local Rule 16.2 in 2007, which requires parties involved in nearly all civil actions to agree upon some form of Alternative Dispute Resolution (ADR) during the litigation process. During the 18-month pilot period that tested Local Rule 16.2, the court found that 51% of...   Read More

Tags:  Gleason Experts

Early Damages Assessment in Data-Intensive Commercial Disputes

January 1, 2017

In the initial phases of litigation, the focus is placed on legal strategy: the analysis of the facts, the development of legal theories, and the research of case law. More practically, the legal team must also weigh the potential damages to be defended/recovered against the legal fees and related costs that will be expended. However,...   Read More

Tags:  Gleason Experts

Alternative Dispute Resolution and the Role of the Financial Expert

January 1, 2017

Alternative Dispute Resolution, or ADR, has the potential to provide parties with an effective means of settling disputes without litigation. As the structure of ADR continues to evolve, so does the role of the financial expert within ADR processes. By involving a financial expert at the early stages of a dispute, it may be possible...   Read More

Tags:  Gleason Experts

Navigating Patent Litigation Changes: Update on the America Invents Act

January 1, 2017

In Issue 3 of IP Insights, we discussed the Inter Partes Review (IPR) process at the United States Patent and Trademark Office (USPTO) since the Leahy-Smith America Invents Act (AIA) was signed into law. The AIA was approved as part of an effort to improve the quality of the patents issued by the USPTO, to...   Read More

Tags:  Gleason IP

Increased Attention on Pharmaceutical Prices

January 1, 2017

As healthcare costs continue to rise, more and more people have entered the debate over escalating drug prices. One situation that has captured the attention of many involves the drug Daraprim®. Daraprim® (pyrimethamine) is used to treat toxoplasmosis in patients with weak immune systems, such as HIV patients.1 Although Daraprim® has been around for over...   Read More

Tags:  Gleason IP

Gleason IP Helps Clients Win Patent Infringement Case

January 1, 2017

Engagement In a pharmaceutical patent infringement matter, Ivan Hofmann and the team at Gleason IP analyzed various issues and provided expert opinions and testimony concerning objective indicia of nonobviousness related to a patent that allegedly covered a lyophilized formulation of the injectable cancer drug bortezomib (marketed as Velcade®). Specifically, Gleason IP analyzed commercial success as...   Read More

Tags:  Gleason IP